版本:
中国

BRIEF-Minerva Neurosciences announces outcome of meeting with FDA

May 15 Minerva Neurosciences Inc

* Minerva announces outcome of end-of-phase 2 meeting with FDA

* Minerva - pivotal phase 3 trial design to include monotherapy administration of MIN-101, primary endpoint of improvement in negative symptoms of schizophrenia

* Minerva Neurosciences Inc - planned initiation of MIN-101 phase 3 development in second half of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐